Darzalex (Daratumumab) for Amyloidosis | MyAmyloidosisTeam

Connect with others who understand.

sign up Log in
About MyAmyloidosisTeam
Powered By

Darzalex is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with multiple myeloma. Darzalex is sometimes prescribed off-label to treat amyloidosis. Darzalex is also referred to by its drug name, daratumumab.

Darzalex is used as a targeted therapy for amyloidosis. Darzalex is a member of a class of drugs called monoclonal antibodies. Darzalex is believed to work by binding to the surface of abnormal cells, causing cell death.

How do I take it?
Prescribing information states that Darzalex is given as an intravenous infusion (slow injection into your vein) by a health care professional. Darzalex is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Darzalex is available as an intravenous infusion.

Side effects
The FDA-approved label for Darzalex lists common side effects including infusion reactions, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, joint pain, back pain, fever, chills, dizziness, insomnia, cough, difficulty breathing, edema (swelling), and nerve problems.

Serious side effects listed for Darzalex include life-threatening infusion reactions, infections resulting from low white blood cell counts, and low blood platelet counts.

For more details about this treatment, visit:

Darzalex – Janssen Biotech

What is Darzalex/Darzalex Faspro? – Multiple Myeloma Research Foundation

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in